IDH2 and diffuse large B-cell lymphoma: Additionally, we identified several vulnerabilities specific to venetoclax-resistant DLBCL cells, including sensitivity to inhibitors of the mitochondrial ETC complex I. Moreover, we demonstrate a novel and potentially synergistic treatment strategy for DLBCL by targeting the redox enzyme IDH2, together with venetoclax, to overcome venetoclax resistance.